Chronic lymphocytic leukemia, or CLL, is the most common type of leukemia in the United States and Europe, mostly affecting people over 55. CLL affects patients in different ways: Some can live with the disease for decades, while it can progress very quickly in others. This makes treating CLL a challenge.
The last 10-15 years have seen dramatic advances in treatment outcomes for thousands of patients with CLL, as new drugs have been developed that target CLL cancer cells with fewer side effects.
MD Anderson’s CLL Moon Shot will combine the latest treatment technology and genetic knowledge to identify the most promising new treatments and move them into a clinical setting in a faster, more efficient way.